Immunome Inc Ordinary Shares IMNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMNM is a good fit for your portfolio.
News
-
Immunome Appoints Sandra M. Swain to Board of Directors
-
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
-
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
-
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
-
Immunome to Participate in the Leerink Partners Global Biopharma Conference
-
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
-
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Trading Information
- Previous Close Price
- $13.73
- Day Range
- $13.70–14.15
- 52-Week Range
- $4.44–30.96
- Bid/Ask
- $13.80 / $13.82
- Market Cap
- $824.97 Mil
- Volume/Avg
- 786,933 / 819,251
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 19.44
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 55
- Website
- https://www.immunome.com
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yjrsgwrls | Mgjh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bnjdzglc | Kcscctd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zkthkvtq | Cyslgy | $97.8 Bil | |
MRNA
| Moderna Inc | Dwhjwfk | Lct | $41.3 Bil | |
ARGX
| argenx SE ADR | Qbzcgsb | Bzwh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Yhntkdrg | Cykgl | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cgqwqqmq | Nxmxt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Twdkklqy | Ssqskg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hktcdddnw | Twwffd | $12.5 Bil | |
INCY
| Incyte Corp | Mszdxmwv | Vpxgpgw | $11.6 Bil |